Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is of fair value on EV/EBITDA, undervalued on P
Target Price
The average target price of KURA is 32 and suggests 275% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell